METHOD FOR CORRECTION OF ELECTROLYTE DISTURBANCES IN PATIENTS WITH CORONAVIRUS INFECTION COVID-19 Russian patent published in 2024 - IPC G01N33/48 A61K33/14 A61K31/573 A61P7/08 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to treatment of infectious diseases, and can be used in correction of electrolyte disorders in patients with coronavirus infection COVID-19. Method involves examination of patients, infusion of preparations of potassium chloride and sodium chloride, assessment of blood cortisol, blood ACTH, potassium and sodium. Before the beginning of the treatment, the blood cortisol level, blood ACTH level, potassium and sodium levels are determined, which respectively have the following values: sodium 130.35 ± 6.5 mmol/l, potassium 3.7 ± 0.6 mmol/l, blood cortisol 454.7 ± 138.5 nmol/l, ACTH 14.8 ± 6.6 nmol/l. If the sodium level is below 135 mmol/l and the potassium level is below 3.5 mmol/l, electrolyte disturbances are corrected by intravenous infusions of potassium and sodium preparations, and if ineffective, hydrocortisone 10 mg is administered orally. Duration of hydrocortisone intake is determined by calculation model of hydrocortisone intake by ACTH level y = 2.6 + 0.08x, where y is the number of days of taking hydrocortisone required to stabilize electrolyte disturbances, x is the level of ACTH, and according to the calculated model of the length of taking hydrocortisone by the level of cortisol by the formula y = 3.3 + 0.001x, where y is the duration of taking hydrocortisone, x is blood cortisol level. 3 days after discontinuation of hydrocortisone and 7 days before discharge from hospital, a control measurement of potassium and sodium levels is performed to control the absence of hypokalaemia and recovery of electrolyte disturbances.

EFFECT: using the invention enables normalizing and restoring electrolyte disturbances in patients with COVID-19.

1 cl, 2 ex